Can you take Vumerity while pregnant or breastfeeding?

Note: This article is for educational purposes only and is not a substitute for medical advice from your neurologist, OB-GYN, primary care clinician, or your baby’s pediatrician.

Here is the frustratingly honest answer: this is not a clean yes-or-no situation. Vumerity can help manage relapsing forms of multiple sclerosis, but pregnancy and breastfeeding change the conversation fast. What works on an ordinary Tuesday may need a full committee meeting once a pregnancy test turns positive.

If you are wondering whether you can take Vumerity while pregnant or breastfeeding, the safest summary is this: during pregnancy, Vumerity is generally not treated as a routine “go ahead” medication, and during breastfeeding, the answer is more nuanced than the official label alone might suggest. The label is cautious, the real-world evidence is still limited, and the right decision usually depends on how active your MS has been, how important breastfeeding is to you, and how comfortable your care team is with uncertainty.

In other words, this is not the moment for cowboy medicine. It is the moment for a coordinated plan.

The short answer

Pregnancy: Vumerity is not usually considered a medication you should casually continue or start during pregnancy. The official prescribing information says there are no adequate data on the developmental risk of Vumerity in pregnant women, and animal studies raised concern for fetal harm. At the same time, human data from dimethyl fumarate, a related MS medication that shares the same active metabolite, have not shown a clear increase in major birth defects or miscarriage. That is somewhat reassuring, but it is not the same thing as proven safety.

Breastfeeding: The official Vumerity label says it is unknown whether the drug or its metabolites are present in human milk and that the effects on the breastfed infant and milk production are unknown. However, lactation experts reviewing related fumarate data have been more reassuring than the label sounds at first glance, especially because the active metabolite appears in milk at low levels and published infant experience has not raised a major red flag. Still, breastfeeding on Vumerity remains a decision that should be individualized.

What is Vumerity, and why does this question matter so much?

Vumerity is the brand name for diroximel fumarate, an oral disease-modifying therapy used to treat relapsing forms of MS in adults. Many people with MS are diagnosed during their childbearing years, so questions about fertility, pregnancy planning, medication timing, labor, postpartum relapse risk, and breastfeeding are not side questions. They are the main event.

The challenge is that pregnancy safety data for MS medications are often incomplete. Randomized drug trials in pregnant patients are rare for obvious ethical reasons. That means doctors usually make decisions by combining official labeling, animal data, pregnancy registry reports, related-drug data, breastfeeding pharmacology, and the patient’s real relapse risk. It is medicine, but with a lot more judgment calls than anyone would prefer.

Vumerity and pregnancy: what the evidence actually says

The official labeling is cautious

The FDA-approved prescribing information for Vumerity does not say the drug is proven safe during pregnancy. Quite the opposite: it says there are no adequate data on the developmental risk associated with use in pregnant women, and it notes that, based on animal findings, the drug may cause fetal harm. That wording matters. It tells clinicians that the absence of a known human disaster is not the same as reassuring evidence.

This is why many neurologists do not treat Vumerity as a default pregnancy medication. If someone is planning to conceive, the discussion often happens before pregnancy, not after. That gives the care team time to think about whether to stop therapy, switch therapy, or plan a short washout period depending on disease activity and timing.

Human data are limited, but not completely empty

Here is where things get more interesting. Vumerity and dimethyl fumarate are different drugs, but they share the same active metabolite, monomethyl fumarate. Because of that, clinicians often look at pregnancy data from dimethyl fumarate when trying to estimate the risk picture for Vumerity.

Those data are somewhat reassuring. Observational reports and registry information for dimethyl fumarate have not shown a clear signal for an increased risk of major birth defects, miscarriage, or other major maternal or fetal complications. In one pregnancy registry described in the current prescribing information, the rate of major birth defects among exposed pregnancies did not show a specific pattern suggesting a drug-related syndrome.

That said, the fine print matters. Most reported exposures happened during the first trimester, study limitations exist, and registry data are not the same as a perfect head-to-head safety trial. So the takeaway is not “Vumerity is proven safe.” The takeaway is more like, “the available human signal is not screaming danger, but it is not strong enough to declare victory.”

Animal data still carry weight

The reason caution remains strong is that animal studies of diroximel fumarate found developmental problems at relevant exposures, including skeletal abnormalities, decreased body weight, increased mortality, and neurobehavioral effects in offspring. Animal data do not predict every human outcome perfectly, but they absolutely influence how pregnancy labeling is written and how specialists frame risk.

When human data are incomplete and animal data are concerning, most clinicians lean toward caution unless there is a compelling reason not to.

So, can you take Vumerity while pregnant?

In practical terms, it is usually not the preferred plan unless the potential benefit clearly outweighs the uncertainty and risk. Many MS specialists stop fumarate-based therapy before conception or once pregnancy is recognized, especially when the disease has been stable.

But there is one huge catch: MS disease activity matters. If you have highly active MS, repeated relapses, MRI changes, or a history that suggests you do poorly off treatment, your neurologist may be much less comfortable with a medication-free pregnancy plan. In those situations, the conversation may shift away from “Can I stay on Vumerity?” and toward “Should we switch to a pregnancy-friendlier strategy before conception?”

That is why stopping Vumerity on your own is not a smart move. Pregnancy raises concerns, yes, but uncontrolled MS is not harmless either. A sudden do-it-yourself medication exit can create a different kind of problem.

Questions to ask your care team before or during pregnancy

• How active has my MS been over the last 6 to 12 months?
• Do you recommend stopping Vumerity before trying to conceive?
• Should I switch to another disease-modifying therapy before pregnancy?
• If I become pregnant unexpectedly while taking Vumerity, what is the plan?
• Do I need a washout period before trying to conceive?
• Should I enroll in a pregnancy exposure registry if I was exposed?
• What is the postpartum treatment plan so I am not making major decisions while sleep-deprived and holding a burp cloth?

What if you find out you are pregnant while taking Vumerity?

First, do not panic. Unplanned exposures happen, and the available fumarate data do not suggest an automatic catastrophe. Second, do not quietly disappear from your medication or internet-search your way into a new treatment plan at 2:14 a.m. Reach out to your neurologist and OB-GYN promptly so they can review your timing, your last dose, your disease history, and whether additional monitoring is appropriate.

It is also worth asking about a pregnancy exposure registry. Registry participation helps improve future knowledge for other patients and may give your team a more structured way to track outcomes.

Vumerity and breastfeeding: a more nuanced answer

What the official label says

The official Vumerity prescribing information is conservative here too. It says there are no data on the presence of diroximel fumarate or its metabolites in human milk, and that the effects on the breastfed infant and on milk production are unknown. On paper, that sounds like a full stop.

But labels are written to be cautious, and they do not always capture how lactation specialists interpret related pharmacology and published case experience.

Why some experts are more reassuring than the label sounds

Again, the key detail is that Vumerity and dimethyl fumarate share the same active metabolite, monomethyl fumarate. LactMed and MotherToBaby review data connected to that metabolite and to dimethyl fumarate exposure, and their summaries are more encouraging than the package insert. Available breastfeeding data suggest that the amount transferred into milk is low and is not expected to cause side effects for most infants.

LactMed goes a step further and notes that, based on clinical data involving more than 20 infants exposed through breast milk to related fumarate therapy, diroximel fumarate is considered acceptable during breastfeeding, at least after the first month of life. That is not a guarantee of zero risk, but it is a meaningful piece of evidence in real-world decision-making.

MotherToBaby also notes that dimethyl fumarate gets into breast milk in small amounts and that some people may choose to reduce infant exposure further by waiting about 4 to 5 hours after a dose before breastfeeding. Since Vumerity is not the exact same drug, that kind of timing strategy should only be used if your clinician thinks it makes sense for your specific situation.

When breastfeeding on Vumerity may be discussed more seriously

Some clinicians may be more open to breastfeeding while taking Vumerity if:

• your MS has enough relapse risk that delaying treatment feels unwise,
• you strongly want to breastfeed,
• your baby is not medically fragile,
• your infant is older than the newborn period, and
• your pediatrician is aware and comfortable helping monitor the baby.

Monitoring may include watching for normal weight gain, development, and possible symptoms such as vomiting, diarrhea, or unusual flushing.

When a care team may lean against breastfeeding on Vumerity

A more cautious approach may be favored if the baby is premature, very young, medically complex, struggling with feeding or weight gain, or if the family simply does not feel comfortable operating in a gray area. Some patients also decide that formula or mixed feeding is the better trade-off if restarting MS treatment quickly feels essential.

There is no gold medal for making the hardest version of the decision. There is only the decision that best protects both parent and baby.

Pregnancy planning with MS: timing matters almost as much as the medication

One of the most helpful things you can do is plan ahead. MS specialists often advise getting disease activity as stable as possible before conception. Some centers suggest aiming for 6 to 12 months of stability before trying to become pregnant. That does not make pregnancy perfect, but it can make it less chaotic.

The postpartum period deserves just as much planning. Pregnancy itself often lowers relapse activity for many patients, but the first few months after delivery can be a higher-risk window for renewed disease activity. That is one reason neurologists like to discuss breastfeeding goals and medication resumption before delivery instead of improvising in the hospital while everyone is exhausted and somebody keeps misplacing the phone charger.

If your MS was very active before pregnancy, early postpartum treatment may be recommended. If your disease burden has been low, some neurologists may be more comfortable deferring treatment while you exclusively breastfeed for a period of time. The right answer depends on your own relapse history, MRI pattern, disability risk, and feeding goals.

Practical takeaways if you are trying to decide

If you are planning pregnancy

• Talk to your neurologist before trying to conceive, not after.
• Ask whether Vumerity should be stopped or whether another strategy makes more sense.
• Review your relapse history and MRI activity honestly, not optimistically.
• Build a postpartum plan now, including how soon you may need to restart treatment.

If you are already pregnant

• Contact your neurologist and OB-GYN promptly.
• Do not make abrupt medication changes without guidance.
• Ask whether registry enrollment is appropriate.
• Review all medications and supplements, not just Vumerity.

If you want to breastfeed

• Discuss the official label and the lactation literature together.
• Ask how high your postpartum relapse risk is if treatment is delayed.
• Make sure your pediatrician knows the plan.
• Monitor your baby’s weight gain, feeding, and general tolerance.

Bottom line

So, can you take Vumerity while pregnant or breastfeeding?

During pregnancy: usually not as a routine default. The official data for Vumerity in pregnancy are limited, animal studies raise concern, and many clinicians prefer to stop it or use another strategy if treatment is still needed.

During breastfeeding: the answer is more individualized. The official Vumerity label says the effects are unknown, but related fumarate data reviewed by lactation experts are more reassuring, especially after the newborn period and with infant monitoring. For some patients, breastfeeding on Vumerity may be a reasonable conversation. For others, it may not be the best fit.

The smartest move is not to ask whether the internet thinks you should do it. The smartest move is to ask whether your neurologist, your OB-GYN, and your pediatrician agree on a plan that fits your disease and your family.

Experiences people commonly report when facing the Vumerity pregnancy or breastfeeding decision

The emotional side of this topic is easy to underestimate. On paper, it looks like a medication question. In real life, it often feels like three questions stacked on top of each other: “What is safest for the baby?” “What is safest for me?” and “Why does it feel impossible to do both at the same time?” Many people with MS describe a kind of decision whiplash. One week they are focused on staying relapse-free, getting through work, and keeping their symptoms calm. The next week they are reading about pregnancy registries, breast milk transfer, postpartum relapse risk, and whether a freezer full of milk can somehow solve a neurology problem. Spoiler: it usually cannot.

A common experience is guilt from every direction. Some people feel guilty about continuing treatment because they worry about fetal or infant exposure. Others feel guilty about stopping treatment because they know a serious relapse could affect their ability to function, work, parent, or recover after delivery. Then breastfeeding enters the chat and somehow makes everything more dramatic. People often say they expected feeding decisions to be emotional, but they did not expect those decisions to be tied so closely to MRI history, relapse counts, and the timing of restarting a disease-modifying therapy.

Another pattern that comes up often is how differently specialists frame risk. A neurologist may focus on preventing postpartum disease activity. An OB-GYN may focus on fetal exposure and pregnancy monitoring. A pediatrician may focus on infant weight gain and medication transfer into milk. None of them are wrong, but patients can feel like they are being asked to merge three expert opinions into one livable plan. That can be exhausting, especially late in pregnancy or early after delivery when sleep becomes a rumor.

People also talk about how helpful it is when the plan is made early. When a patient already knows, “If my disease stays quiet, I will breastfeed for this long and then restart treatment,” or, “If I have a relapse, we will resume medication sooner,” the whole situation feels less scary. The unknown is often harder than the actual decision. Even patients who ultimately choose not to breastfeed, or to wean earlier than planned, often describe feeling calmer once the choice matches their medical reality instead of some perfect-image version of motherhood.

Finally, many patients say the most reassuring part of the process is hearing that there does not have to be a “heroic” choice. You do not need to prove anything by white-knuckling your way through pregnancy off treatment if your disease is aggressive. You also do not need to apologize for wanting to breastfeed if the evidence and your clinicians support a monitored plan. The goal is not perfection. The goal is a healthy parent, a healthy baby, and a treatment strategy that makes sense in the real world.